AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05352932 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: pancreatic duct biopsy
Description: Enrolled patients will undergo a baseline assessment, including CP history, clinical symptoms, imaging tests, laboratory tests, etc.~Then, according to the clinical standard of diagnosis and treatment of chronic pancreatitis, ERCP (with or without Extracorporeal Shock Wave Lithotripsy (ESWL) / endoscopic lithotripsy) will be performed for patients with calculi; pancreatic stent or nasopancreatic stent will be placed for patients with pancreatic duct stenosis. During ERCP, the patient's pancreatic tissue will be biopsied and sent for pathological examination.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Candidate UTI vaccine HTD formulation 2
Description: Candidate UTI vaccine HTD formulation 2 administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06453395 — intervention group
Intervention type: OTHER
Intervention: Patients were grouped according to tumor location
Description: Patients were grouped according to tumor location
Study NCT06702449 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intramuscularly according to a 0, 2 months administration schedule.
Study NCT06719674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Professional mechanical plaque removal and Laser
Description: A diode laser will be used as an adjunct to mechanical plaque removal.
Study NCT06719674 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Professional mechanical plaque removal
Description: The patients will be treated in accordance with treatment guidelines for Stage III periodontitis issued by the European Federation of Periodontology (13). At baseline, oral hygiene instructions were given together with supra- and subgingival professional mechanical plaque removal (PMPR) using a combination of the ultrasonic scaler and hand instruments, according to the clinical situation. After completing treatment, patients will be asked to return at 1 month for review and again at 3 months to repeat the measurement of clinical parameters and collection of the saliva samples.
Study NCT06722755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP device
Description: Eligible participants with OSA will be started on automatically-adjusting CPAP.
Study NCT06722755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP device
Description: Eligible participants with OSA will be started on automatically-adjusting CPAP.
Study NCT06722755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP technical support
Description: Trained personnel will conduct mask selection and fitting, provide continual troubleshooting, and train participants on CPAP.
Study NCT06722755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone follow-up for adherence feedback and self-management skills
Description: The research coordinator will call participants approximately monthly to provide any needed support.
Study NCT06722755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myAir
Description: Study personnel will assist participants in registering for and using the myAir (ResMed) self-tracking app. This app also provides a library of how-to videos and provides email updates to participants.
Study NCT06722755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored messages
Description: Tailored text messages will be sent to participants. Two-way texting messaging will also be available between the study team and participants.
Study NCT06722755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Materials
Description: A binder of written educational materials will be provided to participants.
Study NCT06049446 — intervention group
Intervention type: DEVICE
Intervention: Pintuition
Description: Magnetic seed localization
Study NCT05344222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared LED
Description: The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
Study NCT05344222 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Similar device - Infrared ED
Description: For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
Study NCT04978272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.
Study NCT04978272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DP Placebo
Description: Placebos will be identical appearance to DP.
Study NCT04978272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DP Placebo
Description: Placebos will be identical appearance to DP.
Study NCT04531748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Description: Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.
Study NCT04531748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
Study NCT04531748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo will be used with the same number and appearance to the pills as the interventions.
Study NCT04531748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo will be used with the same number and appearance to the pills as the interventions.
Study NCT05419297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Buccal Film [Belbuca]
Description: buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Study NCT06722755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: A trained sleep coach will conduct up to 5 MET sessions with participants and 2 sessions with a CPAP partner during the study time period.
Study NCT06745882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given on day 1 of every 21-day cycle.
Study NCT06745882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on day 1 of every 21-day cycle.
Study NCT06745882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given on day 1 of every 21-day cycle.
Study NCT06745882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.
Study NCT06745882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Given on days 1, 8, and 15 of each 21-day cycle.
Study NCT06745882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given on day 1 of every 21-day cycle.
Study NCT05951452 — intervention group
Intervention type: OTHER
Intervention: Blood samples for testosterone and SHBG measurements
Description: Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video
Study NCT05951452 — intervention group
Intervention type: OTHER
Intervention: Saliva samples for oxytocin measurements
Description: Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video
Study NCT05419297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urine Drug Screening
Description: Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
Study NCT05419297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urine Drug Screening
Description: Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance
Study NCT05419297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: actigraph
Description: Subjects will wear this device to monitor sleep and activity
Study NCT05419297 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: actigraph
Description: Subjects will wear this device to monitor sleep and activity
Study NCT05419297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS 29
Description: questionnaire will be administered once a week via e-dairy to monitor mood and sleep
Study NCT05419297 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PROMIS 29
Description: questionnaire will be administered once a week via e-dairy to monitor mood and sleep
Study NCT05419297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sit to stand test
Description: Subjects will complete this daily with specific instructions through the e-diary
Study NCT05419297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sit to stand test
Description: Subjects will complete this daily with specific instructions through the e-diary
Study NCT05419297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: numerical rating scale pain score
Description: subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
Study NCT05419297 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: numerical rating scale pain score
Description: subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night
Study NCT05419297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient global impression of function
Description: subjects will be asked three questions once a day to assess their personal impression of functional status
Study NCT05419297 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: patient global impression of function
Description: subjects will be asked three questions once a day to assess their personal impression of functional status
Study NCT05419297 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS - sleep
Description: Subjects will answer 5 questions about sleep every morning via e-diary
Study NCT05419297 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PROMIS - sleep
Description: Subjects will answer 5 questions about sleep every morning via e-diary
Study NCT06756984 — intervention group
Intervention type: PROCEDURE
Intervention: Partial Cyst Wall Resection with Nerve Root Sleeve Plasty
Description: Surgical technique involving partial removal of the cyst wall to decompress the nerve root, followed by plasty of the nerve root sleeve to restore nerve function and prevent recurrence.
Study NCT06756984 — intervention group
Intervention type: PROCEDURE
Intervention: Partial Cyst Wall Resection with Nerve Root Sleeve Reinforcement and Reconstruction:
Description: Advanced surgical technique combining partial cyst wall removal with additional reinforcement and reconstruction of the nerve root sleeve to provide enhanced support and reduce the risk of cyst recurrence.
Study NCT06756984 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous Fat/Muscle with Fibrin Glue Microscopic Cyst Filling
Description: Minimally invasive surgical technique where autologous fat or muscle tissue is used to fill the cyst cavity, and fibrin glue is applied to seal the defect, aiming to obliterate the cyst and prevent cerebrospinal fluid leakage.
Study NCT06754098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxecitine and Doxribtimine
Description: A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
Study NCT06767163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBalance
Description: Participants will engage in the device test, clinical assessment tests. The whole test will last twelve months, and the outcome will be assessed pre- and post-implementation for comparison and validation.~The intervention results are used to compared with traditional tests and clinical diagnosis, to identify whether the sensor provides a higher accuracy in predicting fall risk, and to explore the feasibility of the sensor in clinical scenarios.
Study NCT06768931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biolosion (oral probiotic compound preparation)
Description: Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.
Study NCT06767514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivonescimab Injection
Description: Subject will receive ivonescimab as an IV injection
Study NCT06767514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab Injection
Description: Subject will receive Pembrolizumab as an IV injection
Study NCT06767904 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continous Oxygen by Bottles
Description: Oxygen delivery by bottles giving a continous flow.
Study NCT06767904 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Demand oxygen by Portable Concentrator
Description: Oxygen delivery by consentrators, giving oxygen only when inhaling.
Study NCT06752486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giving post photorefractive keratectomy for pain relief
Description: We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
Study NCT06769724 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction surgery
Description: Anterior cruciate ligament reconstruction surgery with semitendinosus tendon autograft
Study NCT06769724 — intervention group
Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction surgery
Description: Anterior cruciate ligament reconstruction surgery with peroneus longus autograft
Study NCT06769711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedure using Peroneus Longus for ACL reconstruction.
Description: Surgical procedure using Peroneus Longus for ACL reconstruction.
Study NCT06769711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedure using Hamstring tendons for ACL reconstruction.
Description: Surgical procedure using Hamstring tendons for ACL reconstruction.
Study NCT06777199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microscopic Selective Dorsal Neurectomy (SDN)
Description: Selective dorsal neurectomy (SDN) involves microsurgical dissection and partial transection of the dorsal penile nerves to reduce glans sensitivity.~The procedure is performed under spinal anesthesia or local anesthesia with 1% lidocaine.~A midline or dorsal sub-coronal incision is made 1 cm proximal to the coronal sulcus.~The skin is retracted, exposing the Dartos fascia and Buck's fascia to reach the neurovascular bundle (two dorsal penile nerves lateral to two dorsal penile arteries).~Every other nerve on either side of the corpora cavernosa is transected to damage approximately 50% of the nerve supply to the glans.~Suturing is done using 7-0 or 8-0 prolene sutures, and the incision is closed. Patients are evaluated at 1 month and 3 months post-procedure for IELT, AIPE, and PEDT scores to determine success.
Study NCT06777199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) Nerve Ablation
Description: Pulsed radiofrequency (PRF) nerve ablation aims to reduce sensitivity of the dorsal penile nerves using low-energy radiofrequency pulses.~Under sterile conditions, a 22-gauge RF cannula (5-cm-long, 10-mm active tip) is inserted into the flaccid penile skin at the 1-o'clock position for the right dorsal penile nerve.~Sensory stimulation testing is performed at 50 Hz to identify the point of maximum glans sensitivity.~Pulsed radiofrequency is applied at an energy output of 45 V for 180 seconds at 42°C (using the NeuroTherm generator).~The procedure is repeated at the 11-o'clock position for the left dorsal penile nerve, ensuring both sides are treated.~The goal is to ablate sensation over as large an area of the glans as possible without causing permanent nerve damage.~Post-procedure, patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores.
Study NCT06777199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraglanular Hyaluronic Acid (HA) Injection
Description: Intraglanular hyaluronic acid (HA) injection involves administering HA gel into the glans penis to reduce its sensitivity.~The circumference of the glans penis is divided into three circles (1 cm apart, starting from the base), and each circle is further divided into quarter circles.~Topical anesthetic cream (Emla®, lidocaine 25 mg + prilocaine 25 mg) is applied for 30 minutes to numb the glans.~Using two prefilled syringes of HA gel (Hyabell Ultra® 24 mg/ml with 0.3% lidocaine), 12 injections are administered into the deep dermis of the glans using a 27-G needle.~Each injection site receives 0.25 ml of HA gel following the multiple puncture technique.~Patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores to assess efficacy.
Study NCT06781866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: A relaxation type of massage will be used as the main massage intervention in this study. This technique is designed to promote deep relaxation, reduce stress, and enhance overall well-being. It is characterized by the use of five primary techniques performed on the full body, including the palms and feet. Specifically, these techniques consist of effleurage (long, gliding strokes), petrissage (kneading and squeezing), tapotement (rhythmic tapping), friction (deep, circular rubbing), and vibration or shaking movements (Table 1). In addition to these, the technique also incorporates rhythmic movements and deep light pressure to enhance relaxation and alleviate tension. It is designed to promote relaxation, increase blood circulation, relieve muscle tension, improve flexibility and promote relaxation and reduce pain. The total duration of the Relaxation massage is 45 minutes.
Study NCT06781866 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The Sham massage (PLA) will be used as a control session, without applying the deeper techniques that characterize the Relaxation massage in order to eliminate the influence of the human touch sensation on the participant's skin. This massage consisted only of superficial oil application movements over the entire body, without any added pressure or deep muscle manipulation. Oil was used to facilitate smooth gliding, mimicking the sensation of a full massage, but without the intensity or techniques aimed at muscle tissue relaxation. The total duration of the sham massage is 45 minutes.
Study NCT06772727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (lidocaine) will be administered. Patients will receive 1 mg/kg lidocaine of 10 mg/mL lidocaine solution (prepared by diluting 5 mL of lidocaine 20% in saline to a total volume of 10 mL)
Study NCT06772727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: After preoxygenation with 100% oxygen for 3 minutes, the study drug (fentanyl) will be administered. Patients will receive 1 mcg/kg fentanyl of 10 mcg/mL fentanyl solution (prepared by diluting 100 mcg fentanyl in saline to a total volume of 10 mL).
Study NCT06772727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After administration of the study drug, all patients will receive 2 mg/kg propofol intravenously
Study NCT06772727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinyl choline
Description: After loss of consciousness, 1 mg/kg succinyl choline will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.
Study NCT06302140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Nanatinostat
Description: A single oral dose administered on Day 1 in a fasted state.
Study NCT06302140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat (free base) tablets in combination with Valganciclovir
Description: Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.